← Back to Screener
Celularity Inc. Warrant (CELUW)
Price$0.00
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-93.93%
Price vs S&P 500 (4W)-45.55%
VGM Score12.40
All Metrics
Price vs S&P 500 (YTD)-78.12%
10-Day Avg Trading Volume0.03M
3-Month Avg Trading Volume0.02M
52-Week High$0.06
26-Week Price Return-86.00%
13-Week Price Return-73.51%
3-Month Return Std Dev290.05%
Year-to-Date Return-69.94%
5-Day Price Return0.00%
Month-to-Date Return-23.44%
Price vs S&P 500 (13W)-81.77%
Beta1.99x
52-Week Low$0.00
mGradeF
vgmGradeF
Show chart for
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CELUWCelularity Inc. Warrant | — | — | F | $0.00 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Celularity is a clinical-stage biotechnology company developing off-the-shelf, placental-derived cell therapies for cancer, immunologic, infectious, and degenerative diseases. Its pipeline includes natural killer cells, CAR-T cells, and mesenchymal stromal cells, both engineered and unmodified. The company operates through three segments—Cell Therapy, Degenerative Disease, and bio-banking—with bio-banking currently generating the majority of its revenue.